Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea
NCT ID: NCT02541188
Last Updated: 2021-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
460 participants
OBSERVATIONAL
2014-10-02
2017-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer in young women is in the Maghreb
breast cancer in young women (\< 40years old) is in the Maghreb
Genetic analysis
Breast cancer in young women in the western countries
Breast cancer in young women (\< 40years old) in the western countries
Genetic analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Breast cancer proven by histology
* BRCA1/2 analysis proposed, realized, ongoing
* Women \>18 years old
* Patient with insurance
* Patient informed and no-opposed
Exclusion Criteria
* Patient requiring tutorship or guardianship
* Adult patient protected by law
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pascal PUJOL, MDPhD
Role: PRINCIPAL_INVESTIGATOR
Oncogenetic Unit -CHU de Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UF 9428
Identifier Type: -
Identifier Source: org_study_id